Overactive Bladder (OAB) - Drug Pipeline Landscape, 2023

Overactive Bladder (OAB) - Drug Pipeline Landscape, 2023

Overactive bladder (OAB) is a condition in which the bladder muscle contracts too often and causes urinary frequency, urgency, and incontinence. It affects both men and women, but is more common in women.

The causes of overactive bladder include neurological disorders, such as stroke, multiple sclerosis and eak pelvic muscles, diabetes, urinary tract infections, excess consumption of caffeine or alcohol, declining cognitive function due to aging, difficulty walking.

The most common symptoms of overactive bladder include urinary urgency, frequency of urination, urge incontinence and nocturia.

Healthcare provider will look for contributing factors using medical history, physical exam, urine sample to test for infection. Healthcare provider may also recommend urodynamic tests including measuring urine left in the bladder, measuring urine flow rate and testing bladder pressures.

Overactive bladder treatment include behavioral therapies, medications, bladder injections, percutaneous tibial nerve stimulation (ptns) and surgery.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Overactive Bladder treatment such as DA-8010, JLP-2002, YM178 and others. Key players involved in the development of therapies to treat Overactive Bladder are Astellas Pharma Inc, Bayer, Dong-A ST Co Ltd, Jeil Pharmaceutical Co Ltd, Taiho Pharmaceutical Co Ltd and others. Three drugs are under late-stage Phase III clinical trials and three drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development.

Global Insight Service's, Overactive Bladder (OAB) - Drug Pipeline Landscape, 2023 report provides an overview of the Overactive Bladder pipeline drugs. This report covers detailed insights on Overactive Bladder (OAB) drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Overactive Bladder (OAB) pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.